In the last 4C, estimated cash outflows for first quarter 2018 included $200K for R&D, $519K for staff costs, and $300K for Administration and Corporate costs. That is around 4 million dollars for the year if it continues at that rate for the rest of the year. Much of this expense is likely related to development of Kidston Stage 2 rather than operation of Kidston Stage 1.
On the plus side, GENEX is not likely to be paying taxes any time soon:
